retatrutide benefits research weight loss drug reduces fat but also muscle mass Substack Series 3 of 6:

Hypoglycemic medicines in the treatment of Alzheimers disease: Pathophysiological links between AD and glucose metabolism

There are no known interactions with GLP-1 receptor agonists

These should be used according to package instructions and with awareness of any contraindications

The ultimate goal of medical weight loss is sustainability

surgery, however, still offers the most reliable weight loss results of any current obesity intervention

In a large 2-year clinical trial involving 743 patients with a BMI of 2847, those taking orlistat (the active ingredient in Alli) lost, on average, 10.2% of their body weight during the first year, which is significantly more than the 6.1% lost by the placebo group. Patients who continued taking orlistat into the second year regained half as much weight as those who switched to placebo, demonstrating its effectiveness not only for weight loss but also for preventing weight regain. In addition to weight reduction, participants experienced improvements in cholesterol levels, glucose, and insulin concentrations. When used correctly alongside a balanced diet, Alli can be a powerful tool for achieving and maintaining weight loss